国药股份(600511) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 reached ¥13,272,036,678.02, representing a year-on-year increase of 7.12%[2] - The net profit attributable to shareholders for the same period was ¥480,761,109.75, with a slight increase of 0.64% compared to the previous year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥485,951,905.72, reflecting a year-on-year growth of 1.22%[2] - Total operating revenue for the first three quarters of 2024 reached ¥38,028,539,709.49, an increase of 4.1% compared to ¥36,529,666,779.32 in the same period of 2023[18] - Total operating costs for the same period were ¥36,311,068,962.03, up from ¥34,802,634,590.56, reflecting a year-on-year increase of 4.3%[18] - Operating profit for the first three quarters of 2024 was ¥1,989,261,474.35, slightly down from ¥1,993,800,690.24 in 2023, indicating a decrease of 0.1%[18] - Net profit for the first three quarters of 2024 was ¥1,965,833,872.95, compared to ¥1,986,053,916.10 in the previous year, showing a decline of 1.0%[18] - The net profit for Q3 2024 was CNY 1,574,927,175.30, a slight decrease from CNY 1,581,910,864.84 in Q3 2023, representing a decline of approximately 0.2%[19] - The net profit attributable to shareholders of the parent company increased to CNY 1,481,271,832.85 from CNY 1,462,295,886.22, marking an increase of about 1.3% year-over-year[19] - The total comprehensive income for Q3 2024 was CNY 1,570,480,968.80, compared to CNY 1,582,923,924.55 in Q3 2023, indicating a decrease of approximately 0.8%[19] Assets and Liabilities - The total assets of the company at the end of the reporting period amounted to ¥34,336,033,546.56, an increase of 5.80% from the end of the previous year[3] - Total assets increased to ¥34,336,033,546.56 from ¥32,453,092,592.42, marking a growth of 5.8%[16] - Total liabilities rose to ¥15,879,684,150.29, up from ¥14,919,938,717.90, reflecting an increase of 6.4%[16] - The total equity attributable to shareholders increased to ¥16,608,250,755.72 from ¥15,775,887,678.80, representing a growth of 5.3%[16] - The total equity of the company increased to CNY 13.44 billion, up 4% from CNY 12.92 billion in the previous year[24] Cash Flow - The net cash flow from operating activities for the year-to-date was reported as -¥1,029,844,632.09, indicating a significant decline due to extended customer payment cycles and increased payment pressure from bulk procurement[6] - Cash inflows from operating activities for the first nine months of 2024 totaled CNY 39,559,819,298.32, compared to CNY 37,922,608,912.16 in the same period of 2023, an increase of approximately 4.3%[20] - The net cash outflow from operating activities for Q3 2024 was CNY -1,029,844,632.09, a significant decline from a net inflow of CNY 9,221,825.72 in Q3 2023[20] - The company reported cash outflows from financing activities totaling CNY 1,754,026,234.63 in Q3 2024, compared to CNY 1,497,088,198.38 in Q3 2023, indicating an increase of approximately 17.2%[21] - The net cash flow from financing activities was -¥2,712,189,131.53, worsening from -¥1,648,227,509.12 in the same period of 2023[28] Shareholder Information - Total number of common shareholders at the end of the reporting period is 43,368[9] - The largest shareholder, China National Pharmaceutical Group Co., Ltd., holds 412,841,745 shares, accounting for 54.72% of total shares[9] Operational Insights - The company plans to expand its market presence through strategic partnerships and new product launches in the upcoming quarters[17] - There are no significant reminders for investors regarding the company's operational status during the reporting period[13] - The company has not reported any significant changes in shareholder relationships or actions regarding share lending[12] - The company has not provided any audited financial statements for the current reporting period[14] Research and Development - Research and development expenses for the first three quarters were ¥44,141,243.81, down from ¥53,170,617.46, indicating a reduction of 17%[18] - Research and development expenses were not specified for the first three quarters of 2024, but were CNY 4.91 million in the same period of 2023[25]